Faculty

Institution

Unit

Venue

Robert L. Eil

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Otolaryngology - Head And Neck Surgery

Department Of Surgery

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department of Medicine

Division Of Hematology/Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

Department Of Otolaryngology - Head And Neck Surgery

Molecular Biology of Head and Neck Cancer

OHSU Knight Cancer Institute

Department Of Surgery

Surgical Oncology

NoneRobert L. Eil is currently serving as a Biostatistics Shared Resources faculty at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Robert L. Eil

Oregon Health & Science University

You can click a keyword to filter the displayed items

immunology cell biology cancer cells cellular therapy immunotherapy oncology tumor biology cancer immunotherapy immune responses cancer immunosurveillance cancer research cellular immune responses surgical oncology surgery cell signaling cell death cancer biology pharmacology molecular cancer oncogenes liver cancer immunomodulation pancreatic cancer hepatology cell research cancer care gastrointestinal oncology liver physiology cancer discovery adaptive immune system colorectal cancer cell transplantation surgical education t-regulatory cell hepatobiliary tumors tumor suppressors general surgery signaling pathways prognosis liver disease pancreatic surgery lymphocyte development cell metabolism molecular cell biology intensive care clinical medicine cell therapy clinical immunology cell regulation molecular immunology t cells stem cell research immunological memory receptor tyrosine kinases tolerance induction gene editing crispr immunopathology mucosal immunology cellular senescence apoptosis essential genes ionic immune suppression common mechanism ap-1 factors memory t naive cells stem cell memory oxygen sensing receptor-engineered adoptive immunotherapy adoptive immunotherapies regulatory t cells suppressive treg cells suppressive function treg cells cancer immunosuppression

Notable Scholarly Works

Notable Federal Grants

Collaborators

Car T-Cell Therapy for Solid Tumors. Surgical Oncology Clinics of North America (2026)

cell therapysurgerycancer immunotherapysurgical oncologycell transplantationimmunotherapycellular therapy

Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies. Cancer Research Communications (2026)

immunologycell biologyimmunotherapycellular therapypancreatic cancer

Interleukin 6 Drives Durable T Cell-Mediated Immunity to Pancreatic Cancer. Cellular and Molecular Gastroenterology and Hepatology (2026)

oncogenescancer immunotherapycell deathimmunologycell biologyimmunotherapycellular therapyimmune responsesimmunity (medicine)cancer immunosurveillancecellular immune responsespancreatic cancercancer cellscell research

1250 Post-Transcriptional Regulator Hur Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. Regular and Young Investigator Award Abstracts (2025)

oncogenespathologytumor biologypost-transcriptional regulator hurimmunologycell biologytranscription factorsmolecular cancerimmune evasionpancreatic ductal adenocarcinomacancer researchmolecular diagnosticspancreatic cancercancer cellscancer geneticscancer biology

388 Antigen-Dependent Car T Cell Toxicity is Amplified by Neutrophil-Mediated Crosstalk in Epithelial Cancers. Regular and Young Investigator Award Abstracts (2025)

epithelial cancerscancer immunotherapyimmunologycell biologyimmunotherapycellular therapyimmunomodulationimmune responsescellular immune responsescancer immunosurveillanceneutrophil-mediated crosstalkcancer cells

Abstract 4819: Pulmonary Neutrophil-Car T Cell Crosstalk Amplifies Antigen-Specific Off Tumor Toxicity. Cancer Research (2025)

cancer immunotherapyabstract 4819immunologycell biologyimmunotherapylung cancercellular therapyimmunomodulationimmune responsescellular immune responsescancer immunosurveillancetumor toxicitycancer cellsimmune checkpoint inhibitorstumor microenvironment

Abstract 906: High K+ in Tumors Impairs T Cell Effector Activity via Lysosomal Acidification-Induced Autophagy. Cancer Research (2025)

lysosomal acidification-induced autophagytumor biologycancer immunotherapycell deathimmunologycell biologyhigh k+immunotherapycell autophagyautophagycancer cellsabstract 906cancer biology

Abstract A027: Hur Drives Immune Evasion, Metastases and Kras Addiction in Pancreatic Ductal Adenocarcinoma: Implications for Io-Based and Kras Inhibitor Therapies. Cancer Research (2025)

oncogenesmetastasistumor biologyabstract a027cancer immunotherapyimmunologycell biologyimmune evasioncancer researchpancreatic cancertherapeutic targetskras addictioncancer cellscancer biology

NEOOPTIMIZE: Phase II Trial of Adaptive Switching of Neoadjuvant Folfirinox (Ffx) to Gemcitabine/Nab-Paclitaxel (Ga) Resectable/Borderline Resectable (Br)/Locally Advanced (La) Pancreatic Adenocarcinoma (Pdac).. Journal of Clinical Oncology (2025)

adaptive switchingradiation oncologygastrointestinal oncologysurgical oncologymolecular cancercancer researchpancreatic cancerpharmacologyneoadjuvant folfirinoxphase ii trialurologypancreatic surgerycancer treatmentoncology

1383 Elavl1 (Hur) Stabilizes Anabolic and Immunoregulatory Transcripts to Promote Pdac Progression and Immune Evasion. Regular and Young Investigator Award Abstracts (2024)

immunoregulatory transcriptsoncogenesmolecular immunologycell deathcell signalingimmunologycell biologyantiviral responsesimmune evasionpdac progressionimmune dysregulationantiviral researchimmune responsesimmunity (medicine)autophagyclinical immunology

1
2
3
4
5
8
10 / page

Robert L. Eil

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Otolaryngology - Head And Neck Surgery

Department Of Surgery

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department of Medicine

Division Of Hematology/Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

Department Of Otolaryngology - Head And Neck Surgery

Molecular Biology of Head and Neck Cancer

OHSU Knight Cancer Institute

Department Of Surgery

Surgical Oncology

NoneRobert L. Eil is currently serving as a Biostatistics Shared Resources faculty at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Robert L. Eil

Oregon Health & Science University

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Car T-Cell Therapy for Solid Tumors. Surgical Oncology Clinics of North America (2026)

cell therapysurgerycancer immunotherapysurgical oncologycell transplantationimmunotherapycellular therapy

Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies. Cancer Research Communications (2026)

immunologycell biologyimmunotherapycellular therapypancreatic cancer

Interleukin 6 Drives Durable T Cell-Mediated Immunity to Pancreatic Cancer. Cellular and Molecular Gastroenterology and Hepatology (2026)

1250 Post-Transcriptional Regulator Hur Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. Regular and Young Investigator Award Abstracts (2025)

388 Antigen-Dependent Car T Cell Toxicity is Amplified by Neutrophil-Mediated Crosstalk in Epithelial Cancers. Regular and Young Investigator Award Abstracts (2025)

Abstract 4819: Pulmonary Neutrophil-Car T Cell Crosstalk Amplifies Antigen-Specific Off Tumor Toxicity. Cancer Research (2025)

Abstract 906: High K+ in Tumors Impairs T Cell Effector Activity via Lysosomal Acidification-Induced Autophagy. Cancer Research (2025)

lysosomal acidification-induced autophagytumor biologycancer immunotherapycell deathimmunologycell biologyhigh k+immunotherapycell autophagyautophagycancer cellsabstract 906cancer biology

Abstract A027: Hur Drives Immune Evasion, Metastases and Kras Addiction in Pancreatic Ductal Adenocarcinoma: Implications for Io-Based and Kras Inhibitor Therapies. Cancer Research (2025)

oncogenesmetastasistumor biologyabstract a027cancer immunotherapyimmunologycell biologyimmune evasioncancer researchpancreatic cancertherapeutic targetskras addictioncancer cellscancer biology

1383 Elavl1 (Hur) Stabilizes Anabolic and Immunoregulatory Transcripts to Promote Pdac Progression and Immune Evasion. Regular and Young Investigator Award Abstracts (2024)

1
2
3
4
5
8
10 / page